3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
8
Gastrointestinal
8
Head & Neck
2
Genitourinary
2
Dermatologic
2
Plasma cell
1
Lymphoid
1
CNS
1
Breast
1
Conditions
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Interventions
Dexamethasone
136
Lenalidomide
79
daratumumab
77
Bortezomib
66
pomalidomide
48
Cyclophosphamide
48
carfilzomib
43
Calcium Dobesilate
42
Specimen Handling
35
Biopsy
32
Magnetic Resonance Spectroscopy
29
belantamab mafodotin
26
fludarabine
23
isatuximab
22
iberdomide
19
dexamethasone acetate
19
dexamethasone 21-phosphate
19
auricularum
19
Melphalan
18
talquetamab
17
fludarabine phosphate
14
elotuzumab
12
selinexor
11
X-Rays
10
tocilizumab
9
Nivolumab
8
trametinib
7
Whole-Body Irradiation
7
Sirolimus
7
Crizotinib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Erlotinib Hydrochloride
×
Plasma cell
×
90 days
×
Clear all
NCT03297606
2026-03-27
CAPTUR
Canadian Cancer Trials Group
Phase 2
Recruiting
720 enrolled